Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.77 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12400943 | 0.96 | HDAC6 (0.84) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16544776 | 0.95 | HDAC6 (0.68) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL12358936 | 0.92 | HDAC6 (0.66) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL30714411 | 0.92 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL226988 | 0.92 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL2783279 | 0.91 | HDAC6 (0.90) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL17010794 | 0.88 | HDAC6 (0.74) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL12973509 | 0.88 | HDAC6 (0.71) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL26319 | 0.87 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.87 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | VOUDOURIS VASILIOS (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2023-07-18 | — | — | US | disclosed |
| US-20180185279-A1 | Bendamustine Solid Dispersions And Continuous Infusion | VOUDOURIS VASILIOS (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180071263-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2018-03-15 | — | — | US | disclosed |
| US-9907752-B2 | Bendamustine solid dispersions and continuous infusion | VOUDOURIS VASILIOS (US) | 2018-03-06 | — | — | US | disclosed |
| US-9849115-B2 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160310422-A1 | Bendamustine Solid Dispersions And Continuous Infusion | VOUDOURIS VASILIOS (US) | 2016-10-27 | — | — | US | disclosed |
| US-9320730-B2 | Bendamustine solid dispersions and continuous infusion | VOUDOURIS VASILIOS (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150374671-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | CEPHALON INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150258069-A1 | Bendamustine Solid Dispersions And Continuous Infusion | VOUDOURIS VASILIOS (US) | 2015-09-17 | — | — | US | disclosed |
| US-9061011-B1 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150065549-A1 | Bendamustine Pharmaceutical Compositions | VOUDOURIS VASILIOS (US) | 2015-03-05 | — | — | US | disclosed |
| US-8791270-B2 | Bendamustine pharmaceutical compositions | CEPHALON, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20140148490-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | CEPHALON, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310422-A1 | Bendamustine Solid Dispersions And Continuous Infusion | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
| US-20150374671-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FOLR1, FPGS, FLT3 | HDAC6 487/4885HDAC1 3095/4885HDAC3 3718/4885 |
| US-20150065549-A1 | Bendamustine Pharmaceutical Compositions | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20150258069-A1 | Bendamustine Solid Dispersions And Continuous Infusion | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
| US-20180185279-A1 | Bendamustine Solid Dispersions And Continuous Infusion | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
| US-20140148490-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FOLR1, FPGS, FLT3 | HDAC6 487/4885HDAC1 3095/4885HDAC3 3718/4885 |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-11701344-B2 | Bendamustine pharmaceutical compositions | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20180071263-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.